Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 1 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar pchop123 (78.31) Submitted: 11/20/2012 12:22:51 PM : Outperform Start Price: $0.78 PPHM Score: +48.94

some short term upside yet in this one

Featured Broker Partners


Advertisement